We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Zymeworks Inc. (NASDAQ:ZYME) stands against other stocks that insiders bought in April after Trump’s tariff rollout.
President Donald Trump called April 2 a “Liberation Day” after signing an executive order that imposed a minimum 10% tariff on all U.S. imports, with some exceptions. As a result, 57 countries will face higher tariffs ranging from 11% to 50%. While general tariffs took effect on April 5, the elevated rates are set to begin on April 9. These so-called ‘reciprocal tariffs’ triggered retaliation from trade partners and contributed to a decline in the stock market.” On Sunday, Trump said, “I don’t want anything to go down, but sometimes you have to take medicine to fix something,” as reported by CNBC.
The blue-chip companies closed the Monday market session 0.91% lower, while the broader market index closed 0.23% lower after briefly entering bear market territory during the session. The Nasdaq Composite closed 0.10% higher.
Amid these tariff wars and overwhelming market uncertainty, insider trading often comes to focus. Why? When executives buy stock, it can suggest confidence in the company’s future. On the other hand, insider sales don’t have to be a negative sign for the company, because they can reflect personal decisions or investment diversification. This means that insider trading should be considered alongside the company’s financial health and market conditions.
Our Methodology
Today, we’re focusing on stocks that insiders have been buying in April. Using Insider Monkey’s insider trading screener, we identified companies where at least one insider acquired shares from April 2 to April 7. From this list, we ranked the top 20 stocks with the highest value of insider purchases.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A researcher in a lab holding a bispecific antibody, illustrating the leading edge of cancer treatments.
Zymeworks Inc. (NASDAQ:ZYME)
Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company that develops cancer treatments, with its lead candidates including zanidatamab, a HER2-targeted therapy in Phases 1-3 of clinical trials, and zanidatamab zovodotin, a Phase 2 antibody-drug conjugate. The company, based in Middletown, Delaware, is also exploring preclinical oncology programs and collaborating with major partners like BeiGene, Celgene, GlaxoSmithKline, and Merck Sharp & Dohme.
In April, one insider bought $3.62 million worth of Zymeworks shares at an average price of $11.51 per share. Year-to-date, the stock is down 27.94% trading at $10.55 per share. Over the past 12 months, Zymeworks returned 9.67%.
For the full year 2024, Zymeworks (NASDAQ:ZYME) reported revenue of $76.3 million, slightly up from $76.0 million in 2023. The revenue included $25.0 million in milestone payments from Jazz related to the FDA approval of Ziihera for HER2+ BTC treatment. The company incurred $134.6 million in research and development expenses, down from $143.6 million in 2023, and posted a net loss of $122.7 million, compared to a $118.7 million loss the previous year. As of December 31, Zymeworks held $324.2 million in cash, cash equivalents, and marketable securities.
According to MarketBeat, eight analysts rate Zymeworks (NASDAQ:ZYME) stock as a “Moderate Buy” with a price target of $21.00. The average price target suggests an upside of 98.58% from the latest price.
Overall, ZYME ranks 9th on our list of stocks that insiders bought in April after Trump’s tariff rollout. While we acknowledge the potential of ZYME, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZYME but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
